| First Author | Anson M | Year | 2012 |
| Journal | J Clin Invest | Volume | 122 |
| Issue | 2 | Pages | 586-99 |
| PubMed ID | 22251704 | Mgi Jnum | J:184496 |
| Mgi Id | MGI:5424102 | Doi | 10.1172/JCI43937 |
| Citation | Anson M, et al. (2012) Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 122(2):586-99 |
| abstractText | Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Its pathogenesis is frequently linked to liver inflammation. Gain-of-function mutations in the gene encoding beta-catenin are frequent genetic modifications found in human HCCs. Thus, we investigated whether inflammation was a component of beta-catenin-induced tumorigenesis using genetically modified mouse models that recapitulated the stages of initiation and progression of this tumoral process. Oncogenic beta-catenin signaling was found to induce an inflammatory program in hepatocytes that involved direct transcriptional control by beta-catenin and activation of the NF-kappaB pathway. This led to a specific inflammatory response, the intensity of which determined the degree of tumor aggressiveness. The chemokine-like chemotactic factor leukocyte cell-derived chemotaxin 2 (LECT2) and invariant NKT (iNKT) cells were identified as key interconnected effectors of liver beta-catenin-induced inflammation. In genetic deletion models lacking the gene encoding LECT2 or iNKT cells, hepatic beta-catenin signaling triggered the formation of highly malignant HCCs with lung metastasis. Thus, our results identify inflammation as a key player in beta-catenin-induced liver tumorigenesis. We provide strong evidence that, by activating pro- and antiinflammatory mediators, beta-catenin signaling produces an inflammatory microenvironment that has an impact on tumoral development. Our data are consistent with the fact that most beta-catenin-activated HCCs are of better prognosis. |
